Literature DB >> 18521717

Expression profile and prognostic importance in prostate lesions of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57kip2a).

Pinar Atasoy1, Erdal Yilmaz, Onder Bozdogan, Sebnem Ayva, Ertan Batislam.   

Abstract

OBJECTIVES: To investigate expression of the reverse transcriptase component of human telomerase (hTERT) and of cyclin-dependent kinase inhibitor p57 (p57(kip2a)) in prostate neoplasms and evaluate the relationship between these proteins and the Gleason score.
METHODS: hTERT and p57(kip2a) antibodies were studied by immunohistochemical methods in 70 prostate adenocarcinomas (33 high-grade and 37 low-grade carcinomas), 29 benign prostate hyperplasias, and 19 prostatic intraepithelial neoplasias (PIN). Only nuclear staining was evaluated with p57(kip2a) whereas both nuclear and nucleolar staining were evaluated with hTERT.
RESULTS: Immunohistochemical histologic scores (HSCOREs) of hTERT were significantly higher in the PIN group than in the hyperplasia group (P = 0.03). hTERT HSCOREs were not significantly different between hyperplasias and carcinomas or between low and high-grade carcinomas. p57(kip2a) HSCOREs were significantly higher in hyperplasias than other groups, and in PINS than carcinomas, but did not differ significantly between low and high-grade carcinomas. A significant negative correlation was observed between hTERT and p57(kip2a) (P = 0.007) in the hyperplasia group. No such correlation was found in PINs and carcinomas.
CONCLUSIONS: This study suggests that p57(kip2a) is down-regulated in the malignant side of the spectrum of prostate carcinogenesis. Loss of p57(kip2a) control on hTERT might have an important role in the development of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18521717     DOI: 10.1007/s11255-008-9399-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  23 in total

1.  Telomerase reverse transcriptase subunit immunoreactivity: a marker for high-grade prostate carcinoma.

Authors:  Kenneth A Iczkowski; Cooley G Pantazis; Douglas H McGregor; Yaping Wu; Ossama W Tawfik
Journal:  Cancer       Date:  2002-12-15       Impact factor: 6.860

2.  Histone deacetylase inhibitors suppress telomerase reverse transcriptase mRNA expression in prostate cancer cells.

Authors:  Mitsuhiro Suenaga; Hiroshi Soda; Mikio Oka; Akihiko Yamaguchi; Katsumi Nakatomi; Ken Shiozawa; Shigeru Kawabata; Takashi Kasai; Yasuaki Yamada; Shimeru Kamihira; Chuwa Tei; Shigeru Kohno
Journal:  Int J Cancer       Date:  2002-02-10       Impact factor: 7.396

3.  Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription.

Authors:  T Kanaya; S Kyo; K Hamada; M Takakura; Y Kitagawa; H Harada; M Inoue
Journal:  Clin Cancer Res       Date:  2000-04       Impact factor: 12.531

4.  p57KIP2 expression and loss of heterozygosity during immortal conversion of cultured human mammary epithelial cells.

Authors:  T Nijjar; D Wigington; J C Garbe; A Waha; M R Stampfer; P Yaswen
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

5.  Expression-patterns of the RNA component (hTR)and the catalytic subunit (hTERT) of human telomerase in nonneoplastic prostate tissue, prostatic intraepithelial neoplasia, and prostate cancer.

Authors:  Olaf Bettendorf; Bernhard Heine; Sören Kneif; Elke Eltze; Axel Semjonow; Hermann Herbst; Harald Stein; Werner Böcker; Christopher Poremba
Journal:  Prostate       Date:  2003-05-01       Impact factor: 4.104

6.  Expression of human telomerase reverse transcriptase in gastrointestinal stromal tumors occurs preferentially in malignant neoplasms.

Authors:  Muna Sabah; Robert Cummins; Mary Leader; Elaine Kay
Journal:  Hum Pathol       Date:  2004-10       Impact factor: 3.466

7.  Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines.

Authors:  Martha R Stampfer; James Garbe; Tarlochan Nijjar; Don Wigington; Karen Swisshelm; Paul Yaswen
Journal:  Oncogene       Date:  2003-08-14       Impact factor: 9.867

8.  Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens.

Authors:  Mark L Gonzalgo; Christian P Pavlovich; Shing M Lee; William G Nelson
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

9.  hTERT associates with human telomeres and enhances genomic stability and DNA repair.

Authors:  Girdhar G Sharma; Arun Gupta; Huichen Wang; Harry Scherthan; Sonu Dhar; Varsha Gandhi; George Iliakis; Jerry W Shay; Charles S H Young; Tej K Pandita
Journal:  Oncogene       Date:  2003-01-09       Impact factor: 9.867

10.  Immortalization of primary human prostate epithelial cells by c-Myc.

Authors:  Jesús Gil; Preeti Kerai; Matilde Lleonart; David Bernard; Juan Cruz Cigudosa; Gordon Peters; Amancio Carnero; David Beach
Journal:  Cancer Res       Date:  2005-03-15       Impact factor: 13.312

View more
  2 in total

Review 1.  Podocytes proliferate: novel mechanism identified in collapsing glomerulopathies.

Authors:  Cheng Zhu; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-11-08       Impact factor: 2.370

2.  p57(KIP2) control of actin cytoskeleton dynamics is responsible for its mitochondrial pro-apoptotic effect.

Authors:  E Kavanagh; P Vlachos; V Emourgeon; J Rodhe; B Joseph
Journal:  Cell Death Dis       Date:  2012-05-17       Impact factor: 8.469

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.